Mia Celine Borlongan

Ms. Mia Celine Borlongan


Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 October 2023 in Stem Cell Reviews and Reports
Verified
Journal Article
Closed access
PDF file
MBMia Celine Borlongan
Mia Celine Borlongan
DSDipongkor Saha
Dipongkor Saha
Hongbin WangHongbin Wang
Hongbin Wang

Verified
Journal Article
Open access
PDF file
MBMia Celine Borlongan
Mia Celine Borlongan
SRSusanna Rosi
Susanna Rosi
Traumatic brain injury (TBI) is one of the leading causes of long-term neurological disabilities in the world. TBI is a signature disease for soldiers and veterans, but also affects civilians, including adults and children. Following TBI, the brain resident and immune cells turn into a “reactive” state, characterized by the production of inflammatory mediators that contribute to the development of cognitive deficits. Other injuries to the brain, including radiation exposure, may trigger TBI-like pathology, characterized by inflammation. Currently there are no treatments to prevent or reverse the deleterious consequences of brain trauma. The recognition that TBI predisposes stem cell alterations suggests that stem cell-based therapies stand as a potential treatment for TBI. Here, we discuss the inflamed brain after TBI and radiation injury. We further review the status of stem cells in the inflamed brain and the applications of cell therapy in sequestering inflammation in TBI.

3 October 2016 in Chinese Neurosurgical Journal
Verified
Journal Article
Open access
PDF file
MBMia Celine Borlongan
Mia Celine Borlongan
SKSonya Kong
Sonya Kong
DHDavid C. Hess
David C. Hess
Stem cell therapy or “cell therapy” has been demonstrated to be a potent treatment intervention in animal models of acute ischemic stroke, and recently has been introduced as an experimental therapy in early phase clinical trials. Among the many stem cells, the bone marrow adherent cell type known as mesenchymal stem cells have emerged in laboratory studies as a safe and effective therapy for ischemic stroke and other brain diseases. In particular, a unique population of adherent bone marrow-derived cells, called MultiStem cells, display immunomodulatory effects and are a promising allogeneic cell therapy in acute ischemic stroke. Here, we describe the preclinical evidence supporting the use of MultiStem in the acute setting of ischemic stroke and the translation into an early phase clinical trial in ischemic stroke.